The Drug Enforcement Administration seeks to make medication for opioid use disorder readily and safely available to anyone in the country who needs it. As Congressionally-mandated, medical practitioners have a new role to help patients fighting to sustain recovery and prevent opioid overdoses.
The Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all DEA-registered practitioners, except veterinarians, on the treatment and management of patients with opioid or other substance use disorders.
Beginning on June 27, 2023, all DEA-registered and new medical practitioners are required to attest to completion of the training when renewing or completing an initial registration. Below is information on this new requirement.
DEA's Diversion Control Division is pleased to post this joint letter from DEA and HHS supporting the expansion of Medications for Opioid Use Disorder (MOUD). DEA and HHS support the expansion of MOUD especially in rural or underserved areas. DEA is asking its registrants to ensure an adequate and uninterrupted supply of MOUD products when appropriately prescribed and asks distributors to examine any quantitative thresholds they established to ensure that individuals with OUD are able to access buprenorphine. Expanding access to MOUD is one more way to assist patients with OUD during the Opioid Public Health Emergency.
| DEA Administrator Anne Milgram's Statement on MATE Act Requirement (PDF) |
| MATE Act Training Requirements Questions & Answers |
| MATE Act Training Requirements (Video) (June 2023) |
| As Congressionally-mandated, medical practitioners have a new role to help patients fighting to sustain recovery and prevent opioid overdoses. All medical registrants submitting a new or renewing a current registration must attest to completing an eight-hour training to treat patients overcoming opioid and other substance use disorders. |
For information regarding DEA’s Diversion Control Division, contact the Diversion Control Division Policy Section at ODLP@dea.gov if you seek additional assistance regarding this or any other matter.
